JTCS Medtronic Endurant
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Jeffrey H. Shuhaiber
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shuhaiber, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shuhaiber, J. H.
Related Collections
Right arrow Cardiac - pharmacology

J Thorac Cardiovasc Surg 2006;132:732-733
© 2006 The American Association for Thoracic Surgery

Letter to the Editor

I am afraid of using aprotinin because they say so?

Jeffrey H. Shuhaiber, MD

Department of Surgery, Loyola University Stritch School of Medicine, 614-G Laflin, Chicago, IL 60612

(Email: jeffrey01@mac.com).

The first 20% of the full text of this article appears below.

To the Editor:

Cardiothoracic surgeons have become more aware of the worse outcomes associated with aprotinin after cardiac surgery, as discussed in the article by Mangano and colleagues1Go published in the New England Journal of Medicine. It remains an observational study that, as the authors point out, is in need of randomized studies. The main concern of the authors that has not been addressed is the . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 by The American Association for Thoracic Surgery.